Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis

强生将投资5亿美元用于艾滋病和结核病治疗研究

2019-10-08 17:09:04 BioSpace

本文共3485个字,阅读需9分钟

Johnson & Johnson today announced it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis by 2030. As one of the world's largest healthcare companies, Johnson & Johnson is deeply engaged in global health innovation, working closely with governments and strategic partners to improve the health and well-being of more people in more places around the world. "No single institution can tackle the historic challenge of eliminating an infectious disease," said Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. "By advancing our technologies, uniting our best scientists and leveraging decades of experience in HIV and TB, we're optimistic that we can make a significant contribution to the global effort." Building on a strong track record set by its Janssen Pharmaceutical Companies in the areas of HIV and TB and Johnson & Johnson's existing Health for Humanity 2020 Goals, Johnson & Johnson will dedicate a team of world-class researchers who will leverage our scientific resources to accelerate the discovery, development and delivery of next generation medicines and vaccines to complement investments being made by governments. This investment in innovation has the potential to positively impact the day-to-day lives of millions of people affected by both HIV and TB and maximize the efficiency of country investments in health over the long-term. In doing so, these efforts will also support the achievement of the United Nations Sustainable Development Goal 3 targets when combined with other global programs. HIV The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have been committed to the fight against HIV for more than 25 years. Over this time, the Company has introduced eight transformational HIV medicines – including three antiviral agents and five combination products developed in partnership – which have helped to transform HIV/AIDS from a death sentence into a chronic, manageable disease, allowing millions of people living with HIV to lead near normal lives. "Although HIV is now considered a chronic and manageable condition, people living with HIV still face a lifetime of taking daily pills. We therefore must continue to advance important innovations to help them," said Johan Van Hoof, MD, Global Therapeutic Area Head, Vaccines, and Managing Director, Janssen Vaccines & Prevention B.V., Janssen Pharmaceutica NV. "The global challenge remains immense. With 37 million people around the world living with HIV – and nearly two million people newly-infected each year – we cannot treat ourselves out of the HIV epidemic. Our ultimate goal must be to find a preventive vaccine for HIV." As part of the $500 million investment, Janssen will continue to advance an investigational mosaic-based vaccine regimen to prevent HIV together with a consortium of partners. An ongoing efficacy trial (Imbokodo) in 2,600 women in Southern Africa is fully enrolled. A second efficacy trial (Mosaico) is about to commence in North America, South America and Europe with 3,800 men who have sex with men and transgender individuals. In partnership with ViiV Healthcare, Janssen is also investigating a long-acting injectable HIV treatment regimen that could be administered to patients once every two months. This regimen, if approved, could potentially reduce HIV treatment for some patients to just twelve or even six injection visits per year to keep the virus under control, instead of a daily oral treatment taken 365 times per year. Tuberculosis In 2012, Janssen introduced bedaquiline, which was the first TB medicine with a novel mechanism of action in nearly half a century. Since then, the Company has provided more than 145,000 courses of treatment for multidrug-resistant TB (MDR-TB) patients in 131 countries, including through a four-year donation program that operated in the 2015-2019 period in partnership with the U.S. Agency for International Development and JSC Pharmstandard. At the United Nations High-Level Meeting on Tuberculosis in September 2018, Johnson & Johnson announced a comprehensive 10-year initiative to support ending the TB epidemic by 2030, which builds on our current Health for Humanity 2020 TB Goal. With the goal of saving an estimated 1.8 million lives and preventing 12 million new TB infections in the next decade, Johnson & Johnson is working with partners to improve detection of undiagnosed cases of TB, broaden access to bedaquiline, and accelerate research & development (R&D) to discover next-generation TB treatments. "TB is the world's number one infectious killer, and TB and MDR-TB cause major devastation for people, communities and entire countries around the world," says Jaak Peeters, Global Head, Global Public Health, Johnson & Johnson. "The good news is TB is both preventable and treatable, and Johnson & Johnson is committed to doing everything we can to make TB history. With our 10-year initiative we want to unleash the power of science and technology to forever change the trajectory of this terrible disease." Visit www.jnj.com/outsmartepidemics for further details on the breadth of science and collaboration being undertaken by the Johnson & Johnson Family of Companies and its partners to tackle infectious diseases that are pandemics or that have pandemic potential. Annual reporting of progress in delivering Better Health for All can be found in our Health for Humanity Report, which includes details on progress for our Health for Humanity 2020 HIV and TB Goals and our UN Sustainable Development Goals: Global Disease Challenges commitment. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at www.twitter.com/JNJNews. About Johnson & Johnson Health for Humanity 2020 Goals and UN Sustainable Development Goal Commitments We focus our citizenship and sustainability efforts where we believe Johnson & Johnson can achieve the greatest impact by leveraging the power of our people, expertise and global partnerships. Our Health for Humanity 2020 Goals are aligned with our Company's purpose and reflect the areas where our stakeholders expect us to lead. The Sustainable Development Goals (SDGs) are a global framework for progress toward a more sustainable future. In trying to determine the unique impact Johnson & Johnson would contribute to the global community to create a healthier, more equitable world, we developed a clear, pragmatic process to create a commitment to accelerate the SDGs that reflects our unique constellation of strengths. About the Janssen Pharmaceutical Companies At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Vaccines & Prevention B.V. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, regarding development of a potential preventive vaccine for HIV, long acting injectables for the treatment of HIV and novel regimens for the treatment of tuberculosis. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Vaccines & Prevention B.V., or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the company's most recently filed Quarterly Report on Form 10-Q and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-commits-500-million-investment-over-four-years-to-help-end-the-epidemics-of-hiv-and-tuberculosis-300931193.html
强生( Johnson & Johnson )今天宣布,将致力于确保在未来4年内投入超过5亿美元用于世界一流的研发和交付项目,以加快全球到2030年消除艾滋病毒和结核病的努力。强生作为全球最大的医疗保健企业之一,深耕于全球健康创新,与各国政府和战略合作伙伴密切合作,改善世界各地更多地区更多人的健康和福祉。 强生公司执行委员会副主席兼首席科学官 PaulStoffels 医学博士说:“没有任何一个机构能够应对消除传染病的历史性挑战。”“通过推进我们的技术,联合我们最优秀的科学家,并利用几十年来在艾滋病毒和结核病方面的经验,我们乐观地认为,我们能够为全球努力作出重大贡献。” 强生公司将在其杨森(Janssen)制药公司在艾滋病、结核病和强生公司现有的人类健康2020目标领域创造的良好记录的基础上,奉献一支世界级的研究团队,他们将利用我们的科学资源加速这一发现。开发和提供下一代药物和疫苗,以补充各国政府正在进行的投资。 这种对创新的投资有可能对受艾滋病毒和结核病影响的数百万人的日常生活产生积极影响,并最大限度地提高国家对健康的长期投资效率。在这样做的过程中,这些努力还将与其他全球方案相结合,支持实现联合国可持续发展目标3的目标。 艾滋病毒 强生( Janssen )的杨森制药公司(杨森(Janssen))致力于对抗艾滋病病毒25年多。在此期间,该公司推出了8种转型的艾滋病毒药物,包括3种抗病毒药物和5种联合开发的产品,这些药物帮助将艾滋病毒/艾滋病从死刑转变为一种慢性、可管理的疾病,使数百万艾滋病毒感染者能够过上接近正常的生活。 “虽然艾滋病毒现在被认为是一种慢性和可控制的疾病,但艾滋病毒携带者仍然面临着终生服用每日药丸。因此,我们必须继续推进重要的创新来帮助他们,”疫苗全球治疗区负责人、 Janssen 疫苗与预防 B.V .杨森(Janssen) Pharmaceutica NV 董事总经理 Johan Van Hooff 说。“全球挑战依然巨大。全世界有3700万人感染了艾滋病毒,每年有近200万人新感染了艾滋病毒,我们无法摆脱艾滋病。我们的最终目标必须是找到预防艾滋病毒的疫苗。” 作为5亿美元投资的一部分,杨森(Janssen)将继续与一个合作伙伴财团共同推进基于马赛克的疫苗研究养生法,以预防艾滋病毒。南非2600名妇女正在进行一项疗效试验( Imbokodo ),现已全部注册。另一项疗效试验( Mosaico )即将在北美、南美和欧洲开始,共有3800名男性与男性和变性者发生性关系。 与 ViiV Healthcare 合作,杨森(Janssen)还在研究一种长效注射用艾滋病毒治疗养生法,该方案可以每两个月给患者一次。如果该养生法获得批准,可能会使一些患者的艾滋病毒治疗每年减少12次甚至6次,以控制病毒,而不是每年365次的每日口服治疗。 结核病 2012年,杨森(Janssen)推出了贝达奎琳,这是近半个世纪以来第一个具有新作用机制的结核病药物。自那时起,公司已为131个国家的耐多药结核病( MDR-TB )患者提供了145,000多个疗程的治疗,包括通过与美国国际开发署和 JSC Phamstandard 合作在2015-2019年期间实施的四年捐赠计划。 在2018年9月举行的联合国结核病问题高级别会议上,强生公司宣布了一项为期10年的综合举措,以支持到2030年结束结核病疫情,该举措以当前人类健康2020结核病目标为基础。强生公司的目标是在未来十年内挽救约180万人的生命,预防1200万新的结核病感染,该公司正与合作伙伴合作,以改进对未确诊结核病病例的检测,扩大对贝达库林的利用,并加快研发(研发)以发现下一代结核病治疗方法。 “结核病是世界头号传染病杀手,结核病和耐多药结核病给全世界人民、社区和整个国家造成严重破坏,”强生公司全球公共卫生负责人 Jaak Peeters 说。“好消息是结核病是可预防和可治疗的,强生公司致力于尽我们所能创造结核病历史。通过我们的十年计划,我们希望释放科技力量,永远改变这种可怕疾病的发展轨迹。” 请访问 www.jnj.com / supermart 流行病网站,了解强生公司及其合作伙伴为应对大流行或具有大流行潜力的传染病而开展的广泛科学和协作的更多详情。我们的《人类健康促进报告》载有关于实现人人享有更好健康的进展情况的年度报告,其中详细介绍了人类健康2020年艾滋病毒和结核病目标的进展情况,以及我们的联合国可持续发展目标:全球疾病挑战承诺。 关于强生公司 在强生,我们相信良好的健康是充满活力的生活、繁荣的社区和进步的基础。这就是为什么130多年来,我们一直致力于让人们在每一个年龄和每一个生活阶段都保持良好。今天,作为世界上最大和最基础广泛的医疗保健公司,我们致力于利用我们的覆盖面和规模为好。我们努力提高获得和负担能力,创造更健康的社区,并把健康的思想、身体和环境置于每个人都能接触到的地方。我们正在融合我们的心、科学和聪明才智,深刻改变人类健康的轨迹。详情请访问 www.jnj.com 。请访问 www.twitter.com / JNJNews 。 关于强生(Johnson & Johnson) Health for Humanity 2020目标和联合国可持续发展目标承诺 我们将重点放在我们的公民身份和可持续性努力上,我们相信强生公司可以利用我们的员工、专业知识和全球合作伙伴的力量实现最大的影响。我们的2020年人类健康目标与公司的目标一致,并反映了我们的利益相关者期望我们领导的领域。可持续发展目标是实现更可持续未来的全球框架。在试图确定强生公司将为全球社会创造一个更健康、更公平的世界作出贡献的独特影响时,我们制定了一个明确、务实的进程,以建立一个反映我们独特优势的加速 SDG 的承诺。 关于杨森(Janssen)制药公司 在杨森(Janssen),我们正在创造一个疾病是过去的未来。我们是强生( Johnson & Johnson )的制药公司,通过用科学对抗疾病,提高灵巧程度,以及用心脏治疗绝望,不遗余力地为世界各地的患者创造未来。我们专注于医学领域,我们可以作出最大的区别:心血管和新陈代谢,免疫学,传染病和疫苗,神经科学,肿瘤学和肺动脉高压。了解更多信息,请访问 www.janssen.com 。请访问 www.twitter.com / JanssenGlobal 。杨森疫苗预防 B.V .是强生公司杨森(Janssen)制药公司之一。 有关前瞻性陈述的警告 这份新闻稿载有1995年《私人证券诉讼改革法案》所界定的“前瞻性声明”,内容涉及开发一种潜在的艾滋病毒预防疫苗、长期注射用来治疗艾滋病毒和治疗结核病的新方案。读者应注意不要依赖这些前瞻性陈述。这些声明是基于对未来事件的当前预期。如果基本假设被证明不准确或已知或未知的风险或不确定性出现,实际结果可能与 Janssen 疫苗和预防 B.V .、或任何其他杨森(Janssen)制药公司和/或强生公司的预期和预测存在重大差异。风险和不确定性包括但不限于:产品研发固有的挑战和不确定性,包括临床成功和获得监管批准的不确定性;商业成功的不确定性;制造困难和延迟;竞争,包括技术进步;竞争对手获得的新产品和专利;对专利的挑战;导致产品召回或监管行动的产品效力或安全关切;保健产品和服务购买者的行为和支出模式的变化;适用法律和法规的变化,包括全球保健改革;以及保健费用控制的趋势。有关这些风险、不确定性和其他因素的进一步列表和描述,请参见强生公司截至2018年12月30日止财政年度的10-K 表格年度报告,包括标题为“前瞻性声明的谨慎注释”和“第1A 项”的章节。风险因素”,在公司最近提交的10-Q 季报和公司随后提交给美国证券交易委员会的文件中。这些文件的副本可在 www.sec.gov 、 www.jnj.com 或应强生公司要求查阅。杨森(Janssen) Pharmaceutical Companies 和 Johnson & Johnson 均不承诺因新信息或未来事件或发展而更新任何前瞻性声明。 多媒体: http://www.prnewswire.com/news-releases/johnson-johnson-dat-500-million-investment-over-4年来帮助结束艾滋病毒和结核病的流行病-300931193。html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文